Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The advanced lung cancer inflammation index (ALI) is a marker of inflammation, yet its prognostic value in cardiovascular-kidney-metabolic (CKM) syndrome has not been explored. This study examines the relationship between ALI and mortality risk in patients with CKM.
Methods: We analyzed data from 14,301 CKM patients in the National Health and Nutrition Examination Survey (1999–2018). We assessed ALI tertiles (Tertile 1–Tertile 3) using Cox regression, restricted cubic splines, Kaplan-Meier survival curves, and receiver operating characteristic curves. We also performed sensitivity analyses to confirm the robustness of our results.
Results: In a cohort of 14, 301 patients with CKM syndrome, 2,418 deaths from all causes, 765 cardio-cerebrovascular deaths, and 590 cancer-related deaths were recorded. After adjusting for potential confounders, the weighted multivariate Cox model showed that higher ALI was significantly associated with a reduced risk of all-cause and cardio-cerebrovascular mortality (all < 0.001). However, a correlation between ALI scores and reduced cancer mortality was only observed in Tertile 2 for cancer mortality (= 0.01). Smooth curve fitting revealed nonlinear correlations between ALI and mortality across CKM stages 0–4, 0–3, and 4 (log-likelihood ratio test < 0.001). Stratified analyses identified significant interactions between age (P for interaction = 0.03) and smoking status (P for interaction < 0.001) with all-cause mortality, and between chronic kidney disease prognosis and cancer mortality (P for interaction = 0.03) in CKM syndrome patients. Receiver operating characteristic curves confirmed that ALI is a strong predictor of both short- and long-term all-cause, cardio-cerebrovascular, and cancer mortality.
Conclusion: Our study shows that ALI is negatively correlated with all-cause, cardio-cerebrovascular, and cancer mortality within a certain range in patients with CKM syndrome. ALI is an effective prognostic predictor of mortality risk in individuals with CKM syndrome.
Supplementary Information: The online version contains supplementary material available at 10.1186/s12872-025-05019-6.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317444 | PMC |
| http://dx.doi.org/10.1186/s12872-025-05019-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer.
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
Carmezumab combined with albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer with first-line driver PS≤2 negative.
Minerva Surg
September 2025
Unit of Geriatric Medicine, Department of Emergency, Foresea Life Insurance Guangzhou General Hospital, Guangzhou, China -
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
J Thorac Oncol
September 2025
Institut du Thorax Curie-Montsouris, Paris, France; Paris-Saclay University, UVSQ-Versailles, France.
Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.
View Article and Find Full Text PDFReal-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Cancer
September 2025
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.
Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.
Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
N Engl J Med
September 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.